Further, a phase I clinical trial recently identified that the sEH inhibitor-GSK2256294 could ameliorate smoking-induced endothelial dysfunction [75], suggesting that the inhibition of sEH has promising therapeutic applications in COPD. This evidence concerns the gene EPHX2 and endothelial dysfunction.